{"pmid":32293875,"title":"Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms.","text":["Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms.","Since the emergence of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly reported from Wuhan, China, to date, neither a specific vaccine nor antiviral drug against SARS-CoV-2 is available. However, a combination of two HIV-1 protease inhibitors lopinavir and ritonavir has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and the SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations and pair interaction energy analyses based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G*. Both anti-HIV drugs interacted well with the residues at the active site of the SARS-CoV-2 3CL(pro). Ritonavir showed somewhat higher atomic contacts, binding efficiency and key binding residues than that of lopinavir in correspondence with slightly less water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via two hydrogen bond formations. The interactions in terms of electrostatics, dispersion and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.","Biochemistry","Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada","32293875"],"abstract":["Since the emergence of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly reported from Wuhan, China, to date, neither a specific vaccine nor antiviral drug against SARS-CoV-2 is available. However, a combination of two HIV-1 protease inhibitors lopinavir and ritonavir has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and the SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations and pair interaction energy analyses based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G*. Both anti-HIV drugs interacted well with the residues at the active site of the SARS-CoV-2 3CL(pro). Ritonavir showed somewhat higher atomic contacts, binding efficiency and key binding residues than that of lopinavir in correspondence with slightly less water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via two hydrogen bond formations. The interactions in terms of electrostatics, dispersion and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19."],"journal":"Biochemistry","authors":["Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293875","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acs.biochem.0c00160","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295625908225,"score":8.233237,"similar":[{"pmid":32194944,"pmcid":"PMC7062204","title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","text":["Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.","F1000Res","Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin","32194944"],"abstract":["We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes."],"journal":"F1000Res","authors":["Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194944","week":"202012|Mar 16 - Mar 22","doi":"10.12688/f1000research.22457.1","keywords":["*2019-nCoV","*3C-like protease","*COVID-19","*HCV","*Hepatitis C virus","*SARS","*antiviral","*coronavirus","*drug repurpose","*ledipasvir","*molecular modelling","*velpatasvir","*virtual screening"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Sofosbuvir","ledipasvir, sofosbuvir drug combination","ledipasvir","velpatasvir"],"_version_":1663352133535137794,"score":413.49704},{"pmid":32238094,"title":"Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach.","text":["Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach.","Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs ( Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.","J Biomol Struct Dyn","Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer","32238094"],"abstract":["Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs ( Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery."],"journal":"J Biomol Struct Dyn","authors":["Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238094","week":"202014|Mar 30 - Apr 05","doi":"10.1080/07391102.2020.1751298","keywords":["3CLpro","Drug Repurposing","MD Simulation","Remdesivir","SARS-CoV-2","virtual screening,corona viru"],"source":"PubMed","locations":["Chymotrypsin","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Coumarins","remdesivir","Saquinavir","flavone","Darunavir"],"_version_":1663352135603978240,"score":409.48245},{"pmid":32248766,"title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19.","text":["Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19.","A novel coronavirus (SARS-CoV-2) has caused a major outbreak in humans all over the world, and it is the latest pandemic in the series of other infectious diseases. The concept of drug repurposing has been used successfully for many years for known diseases. Considering the emergency and urgency, drug repurposing concept is being explored for coronavirus disease (COVID-19) as well. Recently, the combination of three known drugs, lopinavir, oseltamivir and ritonavir has been proposed to control the virulence to a great extent in COVID-19 affected patients within 48 hours. Hence, we tried to understand the effect of synergism of these drugs against the SARS-CoV-2 protease using sequential docking studies. As a result, combination of three drugs showed a better binding energy than that of individual drugs. Further, the complex was subjected to molecular dynamics simulations to get insights into the stability of the complex, considering the simultaneous interactions between three drugs and the protein. The protein complexed with three drugs remained stable during the simulations. Hence, these drugs can be explored further for drug repurposing against the successful inhibition of COVID-19.","J Biomol Struct Dyn","Muralidharan, Nisha","Sakthivel, R","Velmurugan, D","Gromiha, M Michael","32248766"],"abstract":["A novel coronavirus (SARS-CoV-2) has caused a major outbreak in humans all over the world, and it is the latest pandemic in the series of other infectious diseases. The concept of drug repurposing has been used successfully for many years for known diseases. Considering the emergency and urgency, drug repurposing concept is being explored for coronavirus disease (COVID-19) as well. Recently, the combination of three known drugs, lopinavir, oseltamivir and ritonavir has been proposed to control the virulence to a great extent in COVID-19 affected patients within 48 hours. Hence, we tried to understand the effect of synergism of these drugs against the SARS-CoV-2 protease using sequential docking studies. As a result, combination of three drugs showed a better binding energy than that of individual drugs. Further, the complex was subjected to molecular dynamics simulations to get insights into the stability of the complex, considering the simultaneous interactions between three drugs and the protein. The protein complexed with three drugs remained stable during the simulations. Hence, these drugs can be explored further for drug repurposing against the successful inhibition of COVID-19."],"journal":"J Biomol Struct Dyn","authors":["Muralidharan, Nisha","Sakthivel, R","Velmurugan, D","Gromiha, M Michael"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32248766","week":"202015|Apr 06 - Apr 12","doi":"10.1080/07391102.2020.1752802","keywords":["COVID-19","SARS-CoV-2","drug repurposing","molecular docking","molecular dynamics simulations","protease"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Oseltamivir","Ritonavir","Lopinavir"],"_version_":1663352136207958018,"score":359.39584},{"pmid":32181901,"title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","text":["A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design.","J Med Virol","Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen","32181901"],"abstract":["During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design."],"journal":"J Med Virol","authors":["Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181901","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25768","keywords":["2019-nCoV","BLAST algorithm","CLUSTAL analysis","MERS-CoV","SARS-CoV","coronavirus","homology modeling","sequence alignment"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352133837127680,"score":350.17798},{"pmid":32210741,"pmcid":"PMC7081067","title":"Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.","text":["Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.","Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect. Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease. Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated. Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features. Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses. Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2.","EXCLI J","Ortega, Joseph Thomas","Serrano, Maria Luisa","Pujol, Flor Helene","Rangel, Hector Rafael","32210741"],"abstract":["Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect. Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease. Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated. Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features. Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses. Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2."],"journal":"EXCLI J","authors":["Ortega, Joseph Thomas","Serrano, Maria Luisa","Pujol, Flor Helene","Rangel, Hector Rafael"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32210741","week":"202013|Mar 23 - Mar 29","doi":"10.17179/excli2020-1189","keywords":["Coronavirus","HIV","SARS-CoV-2","protease","treatment"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Saquinavir","Ritonavir","Lopinavir"],"_version_":1663352134926598145,"score":337.742}]}